Year in Review 2024 - Transformative FDA Approvals in Precision Onco…

Oncology 2024 Year in Review

V. Subbiah

Year in Review 2024 - NSCLC Perioperative Therapy

Oncology 2024 Year in Review

B. Halmos

Role of Surgery in Locally Advanced NSCLC

Memorial Sloan Kettering Cancer Center

K. Gray

The Use of IO Doublet in PD-L1-Negative NSCLC

David Carbone

ESMO 2024 Summary: Key Trial Insights on Managing NSCLC With Low PD-…

ecancer

L. Paz-Ares

Adjuvant & Neoadjuvant Therapy in Early NSCLC With Actionable Genomi…

Fox Chase Cancer Center

J. Reuss

ESMO 2024 Summary: Management of Oligoprogressive Disease - Patients…

2024 ESMO Annual Meeting Insights Hub

R. Van den Begin

IO Advances in Metastatic NSCLC Treatment

Fox Chase Cancer Center

H. Borghaei

Lazertinib in 1L EGFR-Mutant NSCLC: Unique Mechanism and Benefits of…

Mariam Alexander

Year in Review 2024 - Top Clinical Trials in Neuro-Oncology

Oncology 2024 Year in Review

S. Bagley

EGFRm Lung Cancer: Overview & Treatment Sequence

GRACE

J. Rotow

Unresectable Stage 3 NSCLC: Patient Selection and Treatment Options

Fox Chase Cancer Center

C. Aggarwal

WCLC 2024 Review: MARIPOSA Trial - Extended Follow Up and Patient Re…

ecancer

E. Felip

Year in Review 2024 - Targeted Therapy for NSCLC

Nebraska Oncology Society

J. Murray

Multidisciplinary Panel Discussion: New Treatment Options for Surgic…

David Carbone

B. Stiles

Neoadjuvant vs. Adjuvant: A New Paradigm for NSCLC

Total Health

D. Carbone

ESMO 2024 Summary: EGFRm NSCLC Panel Discussion - MARIPOSA, PAPILLON…

ecancer

I. Gil-Bazo, M. Brandão, B. Besse, E. Felip

WCLC 2024 Insights: MARIPOSA - Amivantamab + Lazertinib vs. Osimerti…

Insights from 2024 WCLC

S. Gadgeel

WCLC 2024 Insights: Adjuvant vs. Neoadjuvant vs. Peri-Operative Ther…

Insights from 2024 WCLC

J. Von Der Thusen

An Update on Lung Cancer Targeted Therapies: The Evolution of Person…

University of Miami Sylvester Comprehensive Cancer Center

E. Rodriguez